β-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The nature of the progressive beta-cell failure occurring as normal glucose tolerant (NGT) individuals progress to type 2 diabetes (T2DM) is incompletely understood. We measured insulin sensitivity (by a euglycemic insulin clamp) and insulin secretion rate (by deconvolution of plasma C-peptide levels during an oral glucose tolerance test) in 188 subjects [19 lean NGT (body mass index [BMI] </= 25 kg/m(2)), 42 obese NGT, 22 BMI-matched impaired glucose tolerance [IGT], and 105 BMI-matched T2DM]. Main determinants of beta-cell function on the oral glucose tolerance test were derived from a mathematical model featuring the following: 1) glucose concentration-insulin secretion dose response (glucose sensitivity), 2) a secretion component proportional to the derivative of plasma glucose concentration (rate sensitivity); and 3) a potentiation factor. When NGT and T2DM were subgrouped by 2-h plasma glucose concentrations, insulin secretion rate revealed an inverted U-shaped pattern, rising through NGT up to IGT and falling off thereafter. In contrast, beta-cell glucose sensitivity dropped in a monophasic, curvilinear fashion throughout the range of 2-h plasma glucose. Within the NGT range (2-h glucose of 4.1-7.7 mmol/liter), beta-cell glucose sensitivity declined by 50-70% (P < 0.02). Insulin sensitivity decreased sharply in the transition from lean to obese NGT and then declined further in IGT and mild T2DM to level off in the higher three quartiles of diabetic hyperglycemia. In T2DM, defective beta-cell potentiation and rate sensitivity also emerged (P </= 0.05). In the whole data set, insulin sensitivity and the dynamic parameters of beta-cell function explained 89% of the variability of 2-h plasma glucose levels. The following conclusions were reached: 1) beta-cell glucose sensitivity falls already within the NGT range in association with rising 2-h plasma glucose concentrations, although absolute insulin secretion rates increase; and 2) throughout the glucose tolerance range, dynamic parameters of beta-cell function (glucose sensitivity, rate sensitivity, and potentiation) and insulin sensitivity are independent determinants of 2-h plasma glucose levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The slope of the relationship between glucose and insulin secretion (ie, β -CGS) is a major controller of postprandial glu cose levels (23, 24).”
From Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test (2024) · cites this paper as [24]
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Self-citationInsulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 2×
“5] -cell glucose sensitivity (pmol min 1 m 2 mM (1)) 147 [97] 92 [98] 55 [34] 14 [15]”
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
McGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Martin, B. C., Warram, J. H., Krolewski, A. S., Soeldner, J. S., Kahn, C. R., Martin, B. C., & Bergman, R. N. (1992) · The Lancet · doi:10.1016/0140-6736(92)92814-v · Cited by 1,158
Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications
Unger, R. H. (1995) · Diabetes · doi:10.2337/diab.44.8.863 · Cited by 1,100
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Fasting plasma insulin (pmol/liter) 20 [16] 48 [32] 74 [47] 94 [58] Insulin AUC (nmol/liter h) 22 [15] 45 [38] 65 [33] 24 [23] I/ G (pmol/mmol) 73 [84] 163 [172] 122 [140] 19 [33] Fasting ISR (pmol/min m (2)) 53 [34] 85 [53] 116 [39] 112 [71] Total IS (nmol m (2)) 30 [18] 43 [19] 47 [17] 24 [19] Insulin sensitivity (M…”
Cited by
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationManagement of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citationDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationAuthors/Task Force Members, Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,647
Self-citationPathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Self-citationTabák, A. G., Jokela, M., Akbaraly, T. N., Brunner, E. J., Kivimäki, M., & Witte, D. R. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60619-x · Cited by 898
Differentiation of diabetes by pathophysiology, natural history, and prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., et al. (2017) · Diabetes · doi:10.2337/db16-0806 · Cited by 823
“Many different paths, driven by various genetic and environmental factors, result in the progressive loss of b-cell mass (4,5) and/or function (6) that manifests clinically as hyperglycemia.”
BackgroundPancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766
Self-citationAbdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Self-citationβ-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Augustin, L. S. A., Kendall, C. W. C., Jenkins, D. J. A., Willett, W. C., Astrup, A., Barclay, A. W., Björck, I., Brand-Miller, J. C., Brighenti, F., Buyken, A. E., et al. (2015) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.05.005 · Cited by 707
“[56] it is clearly shown that already at the upper end of the normal post-challenge blood glucose ranges (120e140 ng/mL or 6.”
BackgroundType 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
“Approximately 30 – 50% of islet β cell function is lost in individuals with prediabetes ,186 and approximately 10% of people with prediabetes develop DR or polyneuropathy.”
BackgroundThe clinical utility of C‐peptide measurement in the care of patients with diabetes
Jones, A. G., & Hattersley, A. T. (2013) · Diabetic Medicine · doi:10.1111/dme.12159 · Cited by 628
Chen, C., Cohrs, C. M., Stertmann, J., Bozsak, R., & Speier, S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.019 · Cited by 489
Grassi, D., Desideri, G., Necozione, S., Lippi, C., Casale, R., Properzi, G., Blumberg, J. B., & Ferri, C. (2008) · The Journal of Nutrition · doi:10.1093/jn/138.9.1671 · Cited by 481
“Nonetheless, before the presentation of IGT, declines in b-cell function may occur due to sustained hyperglycemia (30).”
BackgroundPathogenesis of Type 2 Diabetes Mellitus
Leahy, J. L. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.003 · Cited by 469
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Self-citationNatural Products for the Treatment of Type 2 Diabetes Mellitus
Ríos, J., Francini, F., & Schinella, G. (2015) · Planta Medica · doi:10.1055/s-0035-1546131 · Cited by 446
Mechanisms of Recovery From Type 2 Diabetes After Malabsorptive Bariatric Surgery
Guidone, C., Manco, M., Valera-Mora, E., Iaconelli, A., Gniuli, D., Mari, A., Nanni, G., Castagneto, M., Calvani, M., & Mingrone, G. (2006) · Diabetes · doi:10.2337/db06-0068 · Cited by 368
Self-citationIslet inflammation in type 2 diabetes and physiology
Eguchi, K., & Nagai, R. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88877 · Cited by 361
Stančáková, A., Javorský, M., Kuulasmaa, T., Haffner, S. M., Kuusisto, J., & Laakso, M. (2009) · Diabetes · doi:10.2337/db08-1607 · Cited by 348
Gastaldelli, A., Gaggini, M., & DeFronzo, R. A. (2017) · Diabetes · doi:10.2337/db16-1167 · Cited by 344
Self-citationβ Cell dysfunction during progression of metabolic syndrome to type 2 diabetes
Hudish, L. I., Reusch, J. E. B., & Sussel, L. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129188 · Cited by 336
“(42) demonstrated that there were stepwise increases in basal insulin secretion and a decreased proportion of glucose-stimulated insulin secretion as individuals moved from normal glucose tolerance to T2DM (Figure 2).”
BackgroundDeFronzo, R. A., & Abdul-Ghani, M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.013 · Cited by 317
Self-citationPathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
“Lower panel: Mean plasma glucose concentration during OGTT.”
BackgroundInfluentialSelf-citationJørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313
“We have compared the -cell glucose sensitivity using DI -GS, which represents an integrated measure of insulin secretion over a longer time period in response to a meal, and this is a sensitive index of -cell responsiveness to glucose, incretin hormones, and nutrients (12, 13, 21).”
MethodMarselli, L., Thorne, J., Dahiya, S., Sgroi, D. C., Sharma, A., Bonner-Weir, S., Marchetti, P., & Weir, G. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011499 · Cited by 313
Link between obesity and type 2 diabetes
Golay, A., & Ybarra, J. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.07.010 · Cited by 301
Janssen, J. A. M. J. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157797 · Cited by 294
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.154 · Cited by 286
Self-citationAssessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction
Thomas, D. D., Corkey, B. E., Istfan, N. W., & Apovian, C. M. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00065 · Cited by 259
“Fasting insulin rises fromnormal glucose tolerance to impaired glucose tolerance (IGT) to T2D [13].”
BackgroundInfluentialImpact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Self-citationPreservation of β-Cell Function: The Key to Diabetes Prevention
DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0246 · Cited by 247
Self-citationType 2 diabetes: A 21st century epidemic
Jaacks, L. M., Siegel, K. R., Gujral, U. P., & Narayan, K. M. V. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.05.003 · Cited by 248
Role of Reduced β-Cell Mass Versus Impaired β-Cell Function in the Pathogenesis of Type 2 Diabetes
Meier, J. J., & Bonadonna, R. C. (2013) · Diabetes Care · doi:10.2337/dcs13-2008 · Cited by 242
“Patients with type 2 diabetes display reductions in the derivative (dynamic) and proportional (static) controls of b-cell functional mass (52,53) and in the incretin effect (44).”
BackgroundHypertension with diabetes mellitus: physiology and pathology
Ohishi, M. (2018) · Hypertension Research · doi:10.1038/s41440-018-0034-4 · Cited by 240
“It is now recognized that β-cell impairment arises and worsens several years before diabetes onset and the initial manifestation of postprandial hyperglycemia [20].”
BackgroundBock, G., Dalla Man, C., Campioni, M., Chittilapilly, E., Basu, R., Toffolo, G., Cobelli, C., & Rizza, R. (2006) · Diabetes · doi:10.2337/db06-0319 · Cited by 230
Reznik, Y., Cohen, O., Aronson, R., Conget, I., Runzis, S., Castaneda, J., & Lee, S. W. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61037-0 · Cited by 233
Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223
Self-citationCunha, D. A., Ladrière, L., Ortis, F., Igoillo-Esteve, M., Gurzov, E. N., Lupi, R., Marchetti, P., Eizirik, D. L., & Cnop, M. (2009) · Diabetes · doi:10.2337/db09-0685 · Cited by 221
“Three lines of evidence support this hypothesis: 1) -Cell function is decreased before clinically detected type 2 diabetes (1,2) (i.”
ResultThiazolidinediones improve β-cell function in type 2 diabetic patients
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2006 · Cited by 200
Self-citationKnop, F. K., Aaboe, K., Vilsbøll, T., Vølund, A., Holst, J. J., Krarup, T., & Madsbad, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01549.x · Cited by 195
“glucose is impaired early in the development of T2DM [34].”
BackgroundResultEsser, N., Utzschneider, K. M., & Kahn, S. E. (2020) · Diabetologia · doi:10.1007/s00125-020-05245-x · Cited by 192
Varra, F.-N., Varras, M., Varra, V.-K., & Theodosis‑Nobelos, P. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13219 · Cited by 190
“IR is responsible for the development of hyperglycemia and over time may evolve to T2dM. ir alone is not capable of causing an increase in blood sugar (292), since the pancreas has mechanisms to adapt, by increasing the mass of β ‑cells and the ability to produce insulin (292,293).”
BackgroundQinna, N., & Badwan, A. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s79885 · Cited by 187
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Merovci, A., Mari, A., Solis, C., Xiong, J., Daniele, G., Chavez-Velazquez, A., Tripathy, D., Urban McCarthy, S., Abdul-Ghani, M., & DeFronzo, R. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3472 · Cited by 186
“-Cell sensitivity to glucose was calculated using the Mari model as previously described (23, 24).”
MethodSelf-citationPathophysiology of prediabetes
Ferrannini, E., Gastaldelli, A., & Iozzo, P. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.11.005 · Cited by 177
Self-citationThe Stunned β Cell: A Brief History
Ferrannini, E. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.009 · Cited by 175
“Furthermore, when insulin secretion rates are reconstructed from C-peptide concentrations (by deconvolution analysis [Cavaghan et al., 2000; Ferrannini et al., 2005]), the pattern is the same: the slope of insulin secretionplasma glucose dose-response relationship is flatter in diabetic than…”
BackgroundMethodSelf-citationKendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 176
“β-Cell impairment is now recognized to arise and worsen years before the onset of diabetes and its initial manifestation of postprandial hyperglycemia [29].”
BackgroundInfluence of Maternal Obesity on Insulin Sensitivity and Secretion in Offspring
Mingrone, G., Manco, M., Valera Mora, M. E., Guidone, C., Iaconelli, A., Gniuli, D., Leccesi, L., Chiellini, C., & Ghirlanda, G. (2008) · Diabetes Care · doi:10.2337/dc08-0432 · Cited by 177
Bergman, M., Manco, M., Satman, I., Chan, J., Schmidt, M. I., Sesti, G., Vanessa Fiorentino, T., Abdul-Ghani, M., Jagannathan, R., Kumar Thyparambil Aravindakshan, P., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111589 · Cited by 171
Jugran, A. K., Rawat, S., Devkota, H. P., Bhatt, I. D., & Rawal, R. S. (2021) · Phytotherapy Research · doi:10.1002/ptr.6821 · Cited by 165
“However, glucose sensitivity of β-cells reduces gradually from diminished glucose tolerance in hyperglycaemia (Ferrannini et al., 2005).”
BackgroundStochastic modelling of insulin sensitivity and adaptive glycemic control for critical care
Lin, J., Lee, D., Chase, J. G., Shaw, G. M., Le Compte, A., Lotz, T., Wong, J., Lonergan, T., & Hann, C. E. (2008) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2007.04.006 · Cited by 162
“Assumptions for these responses could also compromise control accuracy, as both endogenous insulin and glucose productions are known to vary significantly between patients [25-29] and over time.”
BackgroundInsulin Resistance and Mitochondrial Dysfunction
González-Franquesa, A., & Patti, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55330-6_25 · Cited by 173
Dysfunction of Persisting β Cells Is a Key Feature of Early Type 2 Diabetes Pathogenesis
Cohrs, C. M., Panzer, J. K., Drotar, D. M., Enos, S. J., Kipke, N., Chen, C., Bozsak, R., Schöniger, E., Ehehalt, F., Distler, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.033 · Cited by 166
“…insulin dysregulation has been shown to occur in early stages of type 2 diabetes development (AbdulGhani et al., 2006; DeFronzo et al., 2013; Ferrannini et al., 2005), our study provides further insight into underlying mechanisms by demonstrating an intrinsic b cell defect without…”
BackgroundLalić, N. M., Marić, J., Svetel, M., Jotić, A., Stefanova, E., Lalić, K., Dragašević, N., Miličić, T., Lukić, L., & Kostić, V. S. (2008) · Archives of Neurology · doi:10.1001/archneur.65.4.476 · Cited by 149
Pathophysiology of prediabetes
Abdul-Ghani, M. A., & DeFronzo, R. A. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0032-7 · Cited by 177
“Although the mechanism of β-cell failure is poorly understood, a progressive decrease in β-cell sensitivity to glucose occurs as the 2-hour plasma glucose increases [ 39 ].”
BackgroundSelf-citationType 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · Diabetes Care · doi:10.2337/dc11-s221 · Cited by 147
“In two large studies— the San Antonio Metabolism Study (31) (15a) and the Veterans Administration”
BackgroundSelf-citationPersonalized Management of Hyperglycemia in Type 2 Diabetes
Raz, I., Riddle, M. C., Rosenstock, J., Buse, J. B., Inzucchi, S. E., Home, P. D., Del Prato, S., Ferrannini, E., Chan, J. C. N., Leiter, L. A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0512 · Cited by 143
Self-citationHeiskanen, M. A., Motiani, K. K., Mari, A., Saunavaara, V., Eskelinen, J.-J., Virtanen, K. A., Koivumäki, M., Löyttyniemi, E., Nuutila, P., Kalliokoski, K. K., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4627-x · Cited by 142
“Beta cell functional variables have been shown to have distinct patterns of decrease when spanning the range from normoglycaemic obese individuals to those with overt type 2 diabetes [36], and even beta cell defects in impaired fasting glucose and impaired glucose tolerance are different [37].”
BackgroundSelf-citationHaak, T., Meinicke, T., Jones, R., Weber, S., Eynatten, M. V., & Woerle, H. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01590.x · Cited by 140
Ning, F., Tuomilehto, J., Pyörälä, K., Onat, A., Söderberg, S., Qiao, Q., & for the DECODE Study Group (2010) · Diabetes Care · doi:10.2337/dc09-2328 · Cited by 140
“Thus far, none of the studies have restricted the comparison to the individuals with normoglycemia, a category being considered as having relatively low risk for either diabetes (10,17) or CVD (11).”
Backgroundβ-Cell function in type 2 diabetes
Ferrannini, E., & Mari, A. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.012 · Cited by 164
“However, analysis of multiple datasets from crosssectional [51–55] and longitudinal studies [56–58] has demonstrated the β-cell does not respond to insulin resistance by upregulating all its functions.”
BackgroundSelf-citationGastaldelli, A. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70015-8 · Cited by 177
“[40] Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA.”
BackgroundSelf-citationGiannini, C., Weiss, R., Cali, A., Bonadonna, R., Santoro, N., Pierpont, B., Shaw, M., & Caprio, S. (2012) · Diabetes · doi:10.2337/db11-1111 · Cited by 137
Macrophages and islet inflammation in type 2 diabetes
Eguchi, K., & Manabe, I. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12168 · Cited by 135
“Although it appears that high glucose is an essential stimulus for inflammation within islets, recent analysis of β-cell function showed that glucose-induced insulin secretion was already deteriorated before impaired glucose tolerance was detected [38].”
BackgroundRodriguez, L., Reyes, E., Fagalde, P., Oltra, M. S., Saba, J., Aylwin, C. G., Prieto, C., Ramos, A., Galvao, M., Gersin, K. S., et al. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0063 · Cited by 134
Overview of Newer Agents: Where Treatment Is Going
DeFronzo, R. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.008 · Cited by 158
Self-citationAbdul-Ghani, M. A., Williams, K., DeFronzo, R., & Stern, M. (2006) · Diabetes Care · doi:10.2337/dc05-1711 · Cited by 128
Self-citationClinical problems caused by obesity
Kyrou, I., Randeva, H., Barber, T., Tsigos, C., Kaltsas, G. A., & Weickert, M. O. (2022) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33841351 · Cited by 127
Metabolic Abnormalities Underlying the Different Prediabetic Phenotypes in Obese Adolescents
Cali', A. M. G., Bonadonna, R. C., Trombetta, M., Weiss, R., & Caprio, S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1722 · Cited by 124
“muscle and liver) (23, 3 ). Becausetherateofthefirstcomponentisapproximatelyfixed, the increase in basal glucose clearance observed in the adolescents with isolated IGT is due to the metabolic routes accounting for basal glucose effectiveness.”
BackgroundDistinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance
Kanat, M., Mari, A., Norton, L., Winnier, D., DeFronzo, R. A., Jenkinson, C., & Abdul-Ghani, M. A. (2012) · Diabetes · doi:10.2337/db11-0995 · Cited by 122
“b-Cell glucose sensitivity, rate sensitivity, and the potentiation factor were calculated with the model by Mari (12,22).”
MethodSelf-citationTricò, D., Natali, A., Arslanian, S., Mari, A., & Ferrannini, E. (2018) · JCI Insight · doi:10.1172/jci.insight.124912 · Cited by 121
“While IGT is generally associated with reduced β cell glucose sensing (22, 23), the association was paradoxically inverted in hypersecretors.”
BackgroundSelf-citationMathematical models of diabetes progression
De Gaetano, A., Hardy, T., Beck, B., Abu-Raddad, E., Palumbo, P., Bue-Valleskey, J., & Pørksen, N. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90444.2008 · Cited by 119
“Ferrannini et al. (26) reported maximal ISRs ranging from 250 to 1,450 pmol/min in individuals ranging from normal glucose tolerant to T2DM (assuming a BSA of 1.7 m2 for all groups).”
BackgroundInfluentialGlucose regulation of islet stress responses and β‐cell failure in type 2 diabetes
Jonas, J. C., Bensellam, M., Duprez, J., Elouil, H., Guiot, Y., & Pascal, S. M. A. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01112.x · Cited by 118
“Thus, a reduction in first-phase insulin secretion and in β-cell sensitivity to glucose is already detected in individuals in which insulin resistance is still associated with an increase in fasting insulin secretion and in total insulin output during an oral glucose tolerance test, a reduction in the latter parameter…”
BackgroundPolidori, D., Mari, A., & Ferrannini, E. (2014) · Diabetologia · doi:10.1007/s00125-014-3196-x · Cited by 114
“Defects in beta cell function, including reduced insulin secretion and reduced efficiency of proinsulin conversion to insulin, are key pathophysiological factors underlying the hyperglycaemia of patients with type 2 diabetes mellitus [1, 2].”
BackgroundSelf-citationvan Vliet, S., Koh, H.-C. E., Patterson, B. W., Yoshino, M., LaForest, R., Gropler, R. J., Klein, S., & Mittendorfer, B. (2020) · Diabetes · doi:10.2337/db20-0377 · Cited by 114
Atkin, M., Laight, D. W., & Cummings, M. H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.01.003 · Cited by 124
Mari, A., Manco, M., Guidone, C., Nanni, G., Castagneto, M., Mingrone, G., & Ferrannini, E. (2006) · Diabetologia · doi:10.1007/s00125-006-0337-x · Cited by 111
“Rate sensitivity is related to early insulin release [16, 17].”
Self-citationKhetan, A. K., & Rajagopalan, S. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.030 · Cited by 147
β‐cell function assessment from modelling of oral tests: an effective approach
Mari, A., & Ferrannini, E. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00946.x · Cited by 112
Self-citationTargeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 109
Prevention of Diabetes With Pioglitazone in ACT NOW
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., et al. (2013) · Diabetes · doi:10.2337/db13-0265 · Cited by 109
Self-citationThe RISC Investigators, Mari, A., Tura, A., Natali, A., Laville, M., Laakso, M., Gabriel, R., Beck-Nielsen, H., & Ferrannini, E. (2010) · Diabetologia · doi:10.1007/s00125-009-1647-6 · Cited by 120
“In a recent study involving a relatively large number of patients with type 2 diabetes [9], we were unable to confirm the hyperbolic compensation paradigm as the sole mechanism responsible for the emergence of dysglycaemia.”
BackgroundMethodSelf-citationBergman, M., Manco, M., Sesti, G., Dankner, R. S., Pareek, M., Jagannathan, R., Chetrit, A., Abdul-Ghani, M. A., Buysschaert, M., Olsen, M. H., et al. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.09.017 · Cited by 123
Cusi, K., Kashyap, S., Gastaldelli, A., Bajaj, M., & Cersosimo, E. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00624.2006 · Cited by 105
“Therefore, we also examined -cell function as the relationship between plasma C-peptide and glucose concentration during the 48-h administration of acipimox or placebo as an index of insulin secretion dose response to the prevailing plasma glucose concentration, also known as -cell glucose sensitivity (22).”
BackgroundSelf-citationDmitriev, L. F., & Титов, В. Н. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.09.004 · Cited by 117
Manco, M., Panunzi, S., Macfarlane, D. P., Golay, A., Melander, O., Konrad, T., Petrie, J. R., & Mingrone, G. (2010) · Diabetes Care · doi:10.2337/dc09-2261 · Cited by 120
DeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C. (2010) · Diabetes Care · doi:10.2337/dc09-1521 · Cited by 104
Self-citationXiang, A. H., Wang, C., Peters, R. K., Trigo, E., Kjos, S. L., & Buchanan, T. A. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1109 · Cited by 103
“0001 Change during follow-up ( final initial /time) Duration of follow-up (months) 44 (18) 47 (14) 0.”
β-Cell Function in Morbidly Obese Subjects During Free Living
Camastra, S., Manco, M., Mari, A., Baldi, S., Gastaldelli, A., Greco, A. V., Mingrone, G., & Ferrannini, E. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2382 · Cited by 100
Self-citationTomita, T., Masuzaki, H., Iwakura, H., Fujikura, J., Noguchi, M., Tanaka, T., Ebihara, K., Kawamura, J., Komoto, I., Kawaguchi, Y., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0193-8 · Cited by 107
“The insulinogenic index was calculated as the ratio of the insulin concentration (pmol/l) increment to the glucose concentration (mmol/l) increment at 30 min into the OGTT (Δ30insulin/Δ30glucose) [24].”
MethodFunctional Role of miR-155 in the Pathogenesis of Diabetes Mellitus and Its Complications
Jankauskas, S. S., Gambardella, J., Sardu, C., Lombardi, A., & Santulli, G. (2021) · Non-Coding RNA · doi:10.3390/ncrna7030039 · Cited by 113
Burns, N. C., Finucane, F. M., Hatunic, M., Gilman, M., Murphy, M. S., Gasparro, D., Mari, A., Gastaldelli, A., & Nolan, J. J. (2007) · Diabetologia · doi:10.1007/s00125-007-0655-7 · Cited by 108
“The characteristics of beta cell dysfunction in young type 2 diabetic subjects are similar to those we have observed in older diabetic patients [26].”
Self-citationInsufficient Control of Blood Pressure and Incident Diabetes
Izzo, R., SIMONE, G. D., Chinali, M., Iaccarino, G., Trimarco, V., Rozza, F., Giudice, R., Trimarco, B., & LUCA, N. D. (2009) · Diabetes Care · doi:10.2337/dc08-1881 · Cited by 106
Michaliszyn, S. F., Mari, A., Lee, S., Bacha, F., Tfayli, H., Farchoukh, L., Ferrannini, E., & Arslanian, S. (2014) · Diabetes · doi:10.2337/db13-1951 · Cited by 92
Self-citationIn Vivo Insulin Sensitivity and Secretion in Obese Youth
Bacha, F., Gungor, N., Lee, S., & Arslanian, S. A. (2009) · Diabetes Care · doi:10.2337/dc08-1030 · Cited by 90
Emerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Metadata
- Authors
- Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A.
- Affiliations
- University of Pisa (IT)
- The University of Texas at San Antonio Health Science Center (US)
- National Research Council (IT)
- Corresponding author
- Ferrannini, Ele
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-01
- Volume
- 90
- Issue
- 1
- Pages
- 493-500
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1981581852
- Semantic Scholar
- 1e59c003bc095926431f049735ca1064ebb24a32
- Cited by
- 540
- References
- 45
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 20 · 2023: 20 · 2022: 27 · 2021: 19 · 2020: 21 · 2019: 22 · 2018: 25 · 2017: 26 · 2016: 21 · 2015: 33 · 2014: 33 · 2013: 26 · 2012: 32
- FWCI
- 29.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 24092)
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- beta-cell function, type 2 diabetes, impaired glucose tolerance, insulin sensitivity, insulin secretion rate, beta-cell glucose sensitivity, rate dependence, C-peptide, hyperinsulinemic-euglycemic clamp, oral glucose tolerance test, obesity, 2-hour plasma glucose
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Cross-Sectional Studies, Diabetes Mellitus, Fatty Acids, Nonesterified, Female, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Islets of Langerhans, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.